The Food and Drug Administration on Tuesday approved electroCore's gammaCore device to treat cluster headaches.
Patients press the hand held device to their neck, which then sends a mild electrical stimulation to the vagus nerve through the skin to reduce pain associated with cluster headaches.
ElectroCore expects the device to be available in the U.S. later this year.
More articles on supply chain:
Global pharmerging market to reach $1.4B by 2025
Price hikes likely added $8.7B to pharma's net income for 2016, report finds
ASCO: Strategies to control drug costs hinder cancer patient care